Summit Therapeutics Inc.
SMMT
Peringkat dalam Saham
#1713
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$15.67
Kapitalisasi Pasar
$12.50B
Perubahan (1 hari)
7.07%
Perubahan (1 tahun)
-25.37%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Margin Operasi untuk Summit Therapeutics Inc. (SMMT)
Margin Operasi per October 2026 TTM: 0.00%
Menurut laporan keuangan dan harga saham terbaru dari Summit Therapeutics Inc., margin operasi saat ini (TTM) adalah 0.00%. Pada akhir 2023, margin operasi perusahaan adalah 0.00%.
Riwayat margin operasi untuk Summit Therapeutics Inc. dari 2004 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -8,467.05% | 77.72% |
| 2021 | -4,764.29% | -22.97% |
| 2020 | -6,185.23% | 67.28% |
| 2019 | -3,697.51% | 1,669.40% |
| 2018 | -208.97% | -80.63% |
| 2017 | -1,078.65% | -51.91% |
| 2016 | -2,243.17% | 165.64% |
| 2015 | -844.44% | 73.06% |
| 2014 | -487.96% | 93.39% |
| 2013 | -252.32% | 48.37% |
| 2012 | -170.06% | -78.12% |
| 2011 | -777.38% | -74.49% |
| 2010 | -3,047.57% | -57.67% |
| 2009 | -7,198.87% | 1,753.18% |
| 2008 | -388.46% | -8.34% |
| 2007 | -423.82% | 25.04% |
| 2006 | -338.96% | 34.29% |
| 2005 | -252.40% | -89.48% |
| 2004 | -2,400.00% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.